![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Active Filter(s):
Details:
The proceeds will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder (MDD) and CTC-413 for the treatment of Parkinson’s Disease (PD) as well as completion of the development and validation of a diagnostic product for Parkinson’s Disease.
Lead Product(s): Pramipexole Dihydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: CTC-501
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Chinalink Asia Holdings
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 20, 2021